Agilent Technologies Inc. has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
 
All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.
 
“We are delighted to officially welcome the BIOVECTRA team to Agilent,” said Agilent President and CEO Padraig McDonnell. “This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing.”
 
With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.
 
Both BIOVECTRA and Agilent are fully integrated CDMOs with facilities that follow current Good Manufacturing Practices (cGMP), a high standard for methods, facilities, and controls used in manufacturing, processing, and packaging of active pharmaceutical ingredients.

More Mergers & Acquisitions